Tag : MIGRAINE

CONFERENCE UPDATE

Fremanezumab demonstrates efficacy and safety in pediatric patients with episodic migraine: Results from the phase 3 SPACE study
The phase 3 SPACE trial found that fremanezumab significantly decreases episodic migraine frequency in children aged 6 to 17, with notable reductions in monthly migraine days (MMDs) and headache severity compared to placebo.
CONFERENCE UPDATE

Interim analysis of a long-term safety and efficacy extension study of atogepant in episodic and chronic migraine prevention
Atogepant is an oral anti-migraine drug that blocks the calcitonin gene-related peptide (CGRP) receptor.1 It was previously evaluated in the phase 3, randomized, double-blind, placebo-controlled trials ELEVATE and PROGRESS for the prevention of episodic migraine (EM) or chronic migraine (CM), respectively.